•
Sep 30, 2020

Natera Q3 2020 Earnings Report

Natera reported an exceptional quarter with significant volume increase and strong revenue growth driven by new businesses.

Key Takeaways

Natera's Q3 2020 total revenues increased to $98.1 million compared to $77.9 million in Q3 2019, driven by a 39.5% increase in product revenues. The company processed 262,000 tests, including approximately 249,300 tests accessioned in its laboratory. Net loss was $58.3 million, or ($0.72) per diluted share, compared to a net loss of $23.1 million, or ($0.33) per diluted share, for the same period in 2019.

Total revenues reached $98.1 million, a significant increase from $77.9 million in the third quarter of 2019.

Product revenues increased by 39.5% compared to the third quarter of 2019.

Natera processed 262,000 tests in the third quarter of 2020, including approximately 249,300 tests accessioned in its laboratory.

The company is raising its 2020 revenue guidance.

Total Revenue
$98.1M
Previous year: $77.9M
+26.0%
EPS
-$0.72
Previous year: -$0.33
+118.2%
Tests Processed
262K
Previous year: 200.2K
+30.9%
Tests Accessioned
249.3K
Previous year: 187.2K
+33.2%
Total Tests Reported
238.6K
Previous year: 189.6K
+25.8%
Gross Profit
$46.3M
Previous year: $34M
+36.1%
Cash and Equivalents
$810M
Previous year: $51.6M
+1468.9%

Natera

Natera

Forward Guidance

Natera anticipates 2020 total revenue of $380 million to $390 million; 2020 cost of revenues to be approximately 51% to 54% of revenues; selling, general and administrative costs to be approximately $270 million to $280 million; research and development costs to be $90 million to $95 million, and net cash burn to be $140 million to $150 million.